Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:
Diagnostic Utility of Mucosal Impedance Device in Patients With GERD and Chronic Esophageal Disorders:
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: 1\. Patients with chronic esophageal symptoms such as atypical or typical reflux symptoms and dysphagia, is here for upper endoscopy testing. Exclusion Criteria: 1. Presence of esophageal stricture 2. Unstable patients who cannot undergo this testing. 3. Patients on anticoagulation on the day of procedure. 4. Presence of esophageal cancer. 5. Pregnancy. 6. Minor patients.
About the study
Background \& Significance Chronic benign esophageal disorders such as Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis are common gastrointestinal disorders affecting nearly 20% and 0.1% of the population, respectively. Although these conditions are frequent, the diagnosis of GERD or EoE requires complex decision making involving endoscopic examination, histopathological examination, and esophageal pH testing. This translates into significant economic burden; For example, burden due to GERD is about $24 billion annually. Additionally, there may be a delay in the diagnosis of GERD or EoE as Investigators might have to do multiple procedures such as upper endoscopy, esophageal pH testing, etc for the same participant for confirmation of the diagnosis. In addition, there could be overlay between GERD and EoE in the diagnosis which make cause delay in the diagnosis and decision making.
Aim:
Here, Investigators will plan to identify the diagnostic utility and cost-effectiveness of this novel Mivu device(FDA approved) in the diagnosis of gastroesophageal reflux disease or chronic esophageal inflammatory disorders in participants with reflux symptoms or chronic esophageal symptoms.
What is being tested
- MuVI Esophageal mucosal impedance testing (device)
Sponsor: Medical College of Wisconsin · Participants: 50 · Started: Nov 20, 2025
Contact the study team
- Gokulakrishnan Balasubramanian · Phone: 414-805-3827
Official record on ClinicalTrials.gov — NCT07227506
Locations in the U.S.
| Wisconsin | Froedtert Hospital, Milwaukee |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.